The short version of SR9009 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-01-29. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | SR9009; Stenabolic | Nickname is not a chemical name. |
| Typical analytical method | LC-MS/MS | Often with isotope-labeled internal standard. |
| Storage temperature | -20 °C | Desiccated and protected from light. |
| Solution stability | DMSO stock; avoid freeze-thaw | Store at -20 to -80 °C. |
| Regulatory status | Not approved; varies by country | May be restricted as research chemical. |
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
=== Disease === The normal bone marrow architecture can be damaged or displaced by aplastic anemia, malignancies such as multiple myeloma, or infections such as tuberculosis, leading to a decrease in the production of blood cells and blood platelets. The bone marrow can also be affected by various forms of leukemia, which attacks its hematologic progenitor cells. Furthermore, exposure to radiation or chemotherapy will kill many of the rapidly dividing cells of the bone marrow, and will therefore result in a depressed immune system. Many of the symptoms of radiation poisoning are due to damage sustained by the bone marrow cells. To diagnose diseases involving the bone marrow, a bone marrow aspiration is sometimes performed. This typically involves using a hollow needle to acquire a sample of red bone marrow from the crest of the ilium under general or local anesthesia.
== See also == Bioenergetic systems Exercise intolerance § low ATP reservoir Exercise intensity § fuel used Purine nucleotide cycle § pathology (low ATP reservoir, ADP>ATP, ↑AMP) Tachycardia § sinus (inappropriate rapid heart rate response to exercise) IST § differential diagnoses (inappropriate sinus tachycardia) Second wind (exercise phenomenon) Inborn errors of carbohydrate metabolism Fatty acid metabolism disorder (fatty acid oxidation disorder, FAOD) Mitochondrial myopathies AMP deaminase deficiency (myoadenylate deaminase deficiency, MADD)
=== Main === Kathy Bates as Madeline "Matty" Matlock / Madeline Kingston, who claims to be a widowed lawyer, returning to the workforce following decades of retirement due to financial distress from her husband's gambling troubles, and having to raise her grandson following her daughter's death in a car accident. Matlock takes a job as an associate at the law firm Jacobson Moore, working with Olympia, a junior partner at the firm who becomes her boss. In fact, Kingston is wealthy and happily married, though indeed grieving the loss of her daughter who died from an opioid overdose and seeking retribution. She gave herself the alias of "Matlock" after the original television series. Skye P. Marshall as Olympia Lawrence, a junior partner at Jacobson Moore who becomes Matlock's boss. In the pilot episode, she is in the midst of divorcing Julian while aiming at a senior partner role with the support of her father-in-law. Olympia is reluctant to take Matty under her wing as she acknowledges that Matty is the threat to her promotion in the law firm due to her exceptional skills. Jason Ritter as Julian Markston, a senior partner at Jacobson Moore. In the pilot episode, he is in the midst of divorcing Olympia and engaged in a major settlement action involving a large pharmaceutical corporation. David Del Rio as Billy Martinez (seasons 1–2), a first-year associate at Jacobson Moore working with Olympia. Del Rio makes his last appearance in episode 7 of the second season following his dismissal from the series.
Schwann cells are active in Wallerian degeneration. They not only have a role in phagocytosis of myelin, but they also have a role in recruitment of macrophages to continue the phagocytosis of myelin. The phagocytic role of Schwann cells has been investigated by studying the expression of molecules in Schwann cells that are typically specific to inflammatory macrophages. Expression of one such molecule MAC-2, a galactose-specific lectin, is observed in not only degenerating nerves that are macrophage-rich but also degenerating nerves that are macrophage-scarce and Schwann cell-rich. Furthermore, the effects of MAC-2 in degenerating nerves are associated with myelin phagocytosis. There was a positive correlation between the amount of MAC-2 expression and the extent of myelin phagocytosis. A deficiency in MAC-2 expression can even cause inhibition of myelin removal from injury sites. Schwann cells are active in demyelination of injured nerves before macrophages are even present at the site of nerve injury. Electron microscopy and immunohistochemical staining analysis of teased nerve fibers shows that before macrophages arrive at the injury site, myelin is fragmented and myelin debris and lipid droplets are found in the cytoplasm of Schwann cells, indicating phagocytic activity before macrophages arrive. Schwann cell activity includes recruitment of macrophages to the injury site. Monocyte chemoattractant protein (MCP-1) plays a role in recruiting monocytes/macrophages.
Sources: en.wikipedia.org
=== Women's rights === Bhutto Zardari is a strong advocate of "peaceful, progressive, prosperous, democratic Pakistan", what he calls his mother's vision. In an interview with the BBC, he said that his 2018 election campaign was to implement these principles. He is a strong supporter of women's empowerment and believes in empowering women and taking them on board in all matters is the sole guarantee of the country's progress. On the occasion of International Day of the Girl Child, the PPP chairman said that a future based on progress and prosperity could remain a dream without empowering girls and taking them on board in all matters. Bhutto Zardari acknowledged all those women who stepped forward in all sections of life and field while defeating many impediments at every level and social taboos. He specifically named Fatima Jinnah, Benazir Bhutto, Asma Jehangir, and Maryam Mukhtar. On 17 March 2019, Bhutto Zardari met with a delegation of women's rights activists led by Sheema Kirmani and assured his support for their cause. A statement released by Bhutto Zardari House later said that his party would not tolerate any offence against the struggle for gender equality and women's rights. The statement went further to read, "The PPP chairman extended his enduring support to the members of the Aurat March and its activists who are struggling for their genuine and legitimate rights as enshrined in the unanimous constitution of Pakistan." Bhutto Zardari has also advocated for the abolishment of child marriages in Pakistan.
The reaction often affords a mixture of products comprising various pyridines as well as quinolines, isoquinolines, and nitrogen-free compounds. However, the outcome can be controlled to a limited extent by appropriate choice of reaction conditions and catalysts. For example, three molecules of acetaldehyde and one molecule of ammonia predominantly yield picolines. The results can be improved by using ammonia or its equivalent in excess.
The New Union Treaty (Russian: Новый союзный договор, romanized: Novyy soyuznyy dogovor) was a 1990 draft treaty that would have replaced the 1922 Treaty on the Creation of the Union of Soviet Socialist Republics (USSR) to salvage and reform the USSR. The preparation of this treaty was known as the Novo-Ogaryovo process, named after Novo-Ogaryovo, a governmental estate where the work on the document was carried out and where Soviet President and CPSU General Secretary Mikhail Gorbachev talked with leaders of Union republics. A ceremony of the Russian SFSR signing the treaty was scheduled for 20 August 1991, but was prevented by the August Coup. In its aftermath, the Soviet Union ultimately dissolved by December of the same year, and the Commonwealth of Independent States was set up in its place.
== Adverse effects == Common side effects include low blood pressure, cough, hyperkalemia, headache, dizziness, fatigue, nausea, and kidney impairment. The main adverse effects of ACE inhibition can be understood from their pharmacological action. The other reported adverse effects are liver problems and effects on the fetus. Kidney problems may occur with all ACE inhibitors that directly follows from their mechanism of action. However, the decrease may be significant in conditions of pre-existing decreased renal perfusions, such as renal artery stenosis, heart failure, polycystic kidney disease, or volume depletion. In these patients, the maintenance of GFR depends on angiotensin-II-dependent efferent vasomotor tone. Therefore, renal function should be closely monitored over the first few days after initiation of treatment with ACE inhibitor in patients with decreased renal perfusion. Generally, a moderate reduction in renal function (no greater than 30% rise in serum creatinine which stabilizes within 2–4 weeks) is considered acceptable as part of the therapeutic effect. Reduced GFR is especially a problem if the patient is concomitantly taking an NSAID and a diuretic. When the three drugs are taken together, the risk of developing renal failure is significantly increased. Hyperkalemia, or high blood potassium, is a common adverse effect of treatment in 2% to 6% of patients. Suppression of angiotensin II leads to a decrease in aldosterone levels. Since aldosterone is responsible for increasing the excretion of potassium, ACE inhibitors can cause retention of potassium.
Passive smoke is a mixture of smoke from the burning end of a cigarette, pipe or cigar, and the smoke exhaled from the lungs of smokers. It is involuntarily inhaled, lingers in the air hours after cigarettes have been extinguished, and may cause a wide range of adverse health effects, including cancer, respiratory infections, and asthma. Studies have shown that exposure to passive smoke causes harmful effects on the cardiovascular system and is associated with prevalent heart failure among non-smokers. Non-smokers who are exposed to passive smoke at home or work are thought, due to a wide variety of statistical studies, to increase their heart disease risk by 25–30% and their lung cancer risk by 20–30%. According to the World Health Organization, passive smoke is reported to kill about 1 million people per year and causes numerous diseases including cancer and heart diseases. The current US Surgeon General's Report concludes that there is no established risk-free level of exposure to passive smoke. Short exposures to passive smoke are believed to cause blood platelets to become stickier, damage the lining of blood vessels, decrease coronary flow velocity reserves, and reduce heart rate variability, potentially increasing the mortality of heart attacks. New research indicates that private research conducted by cigarette company Philip Morris in the 1980s showed that passive smoke was toxic, yet the company suppressed the finding during the next two decades.
Sources: en.wikipedia.org
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.
Solid material is usually kept at -20 °C, desiccated, and protected from light. Dimethyl sulfoxide stocks should be stored cold and subjected to minimal freeze-thaw cycles. Aqueous solutions are generally less stable and should be prepared fresh when possible.
Legality depends on the country and the intended use. It is not an approved medicine, and some places restrict or ban sales for human consumption. Buyers should verify local rules and product documentation before procurement.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.